You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The deals with Stratose, USA Managed Care Organization, and Evolutions Health Systems provides covered access to the test to more than 21 million patients.
The plan will cover the gene expression test for prostate cancer aggressiveness for all men with localized disease.
Biocept's liquid biopsy diagnostic services are available to approximately 68 million people in MultiPlan's national PPO and complementary network.
Discovery's clients will be able to receive genomic sequencing services, including exome sequencing and analysis for $250 through its Vitality program.
The deal provides Tufts Health Plan members with access to the ConfirmMDx test for prostate cancer.
The agreement covers 43 million people in the US and includes Sequenom's MaterniT21 Plus and HerediT CF and Universal tests.
The agreements with the PPOs bring the total number of Americans with covered access to Biocept's tests to about 31 million.
Starting Sept. 15, Cologuard will be available to BCBS' 500,000 members through their physicians without a co-payment or co-insurance.
The contracts with Stratose, Three Rivers Provider Network, and Fortified Provider Network provide coverage for Opko's testing services.
The medical policy update makes the unnamed insurer the first commercial plan to cover ThyraMIR, a microRNA gene expression classifier launched earlier this year.
A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.
Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.
Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.
In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.